Overview of potential drugs for the treatment of new coronavirus Infection (COVID-19)
https://doi.org/10.29413/ABS.2021-6.4.7
Abstract
The new coronavirus infection (SARS-CoV-2), better known as COVID-19, quickly evolved into a worldwide pandemic with a significant public health burden. Currently, there are no approved drugs or preventive therapeutic strategies to combat infection. Decisions about prescribing many medications are made based on the results obtained in in vitro studies, or expert opinions. Most of the drugs currently used to treat COVID-19 are approved antivirals or antibodies against other diseases. However, there are hundreds of clinical studies underway around the world to discover effective treatments for COVID-19. This article summarizes the results of clinical studies of potential therapeutic drugs used as COVID-19 therapy. Based on this review, it can be concluded that there is still no high-quality evidence to support any of the drugs described below. Until the unambiguous results of randomized controlled trials are available, the use of any of the following drugs is not clinically proven as an effective treatment for COVID-19.
About the Authors
Ya. E. Shirobokov
Samara State Medical University
Russian Federation
Russian Federation
Postgraduate at the Department of Pharmacy Management and Economics
Chapayevskaya str. 89, Samara 443099, Russian Federation
E. P. Gladunova
Samara State Medical University
Russian Federation
Russian Federation
Dr. Sc. (Pharm.), Docent, Professor at the Department of Pharmacy Management and Economics
Chapayevskaya str. 89, Samara 443099, Russian Federation
E. A. Borodulina
Samara State Medical University
Russian Federation
Russian Federation
Dr. Sc. (Med.), Professor, Head of the Department of Phthisiology and Pulmonology
Chapayevskaya str. 89, Samara 443099, Russian Federation
A. E. Sukhanova
Samara State Medical University
Russian Federation
Russian Federation
Resident at the Department of Phthisiology and Pulmonology
Chapayevskaya str. 89, Samara 443099, Russian Federation
References
1. Borodulina EA, Shirobokov YaE, Gladunova EP, Kudlаy DA. Virus-associated lung disease Clinical Pharmacology and Therapy. 2020; 29(3): 61-66. (In Russ.). doi: 10.32756/ 0869-5490-2020-3-61-66
2. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020; 39(6): 1011-1019. doi: 10.1007/s10096-020-03874-z
3. Lvov DK, Kolobukhina LV, Deryabin PG Coronavirus infection. Severe acute respiratory syndrom. Infectious Diseases. News, Opinions, Training. 2015; 4(13): 35-42. (In Russ.)
4. Principi N, Bosis S, Esposito S. Effects of coronavirus infections in children. Emerg Infect Dis. 2010; 16(2): 183-188. doi: 10.3201/eid1602.090469
5. Gagneur A, Vallet S, Talbot PJ, Legrand-Quillien MC, Picard B, Payan C, et al. Outbreaks of human coronavirus in a paediatric and neonatal intensive care unit. Eur J Pediatr. 2008; 167(12): 1427-1434. doi: 10.1007/s00431-008-0687-0
6. Tarighi P, Eftekhari S, Chizari M, Sabernavaei M, Jafari D, Mirzabeigi P. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol. 2021; 895: 173890. doi: 10.1016/j.ejphar.2021.173890
7. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5): 766-788. doi: 10.1016/j.apsb.2020.02.008
8. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of Umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2021; 93(1): 481-490. doi: 10.1002/jmv.26256
9. Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. Effect of Arbidol (Umifenovir) on COVID-19: A randomized controlled trial. BMC Infect Dis. 2020; 20(1): 954. doi: 10.1186/s12879-020-05698-w
10. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and metaanalysis. Virol J. 2020; 17(1): 141. doi: 10.1186/s12985-020-01412-z
11. Siordia JA Jr, Bernaba M, Yoshino K, Ulhaque A, Kumar S, Bernaba M, et al. Systematic and statistical review of coronavirus disease 19 treatment trials. SN Compr Clin Med. 2020 Jul 15: 1-12. doi: 10.1007/s42399-020-00399-6
12. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with Favipiravir for COVID-19: An open-label control study. Engineering (Beijing). 2020; 6(10): 1192-1198. doi: 10.1016/j.eng.2020.03.007
13. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – Final report. N Engl J Med. 2020; 383(19): 1813-1826. doi: 10.1056/NEJMoa2007764
14. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of Remdesivir for patients with severe COVID-19. N Engl J Med. 2020; 382(24): 2327-2336. doi: 10.1056/NEJMoa2007016
15. Young B, Tan TT, Leo YS. The place for Remdesivir in COVID-19 treatment. Lancet Infect Dis. 2021; 21(1): 20-21. doi: 10.1016/S1473-3099(20)30911-7
16. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermectin in COVID nineteen study. Chest. 2021; 159(1). 85. doi: 10.1016/j.chest.2020.10.009
17. Hashim A, Mohammed FM, Anwar MR, Dhurgham FF, Khulood KK, Ahmed SA. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020. doi: 10.1101/2020.10.26.20219345
18. ClinacalTrials.gov. URL: https://clinicaltrials.gov/ct2/results?term=ivermectin&recrs=abcdefghl&cond=covid19 [Date of access: 20.07.2021].
19. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: A cohort study. Lancet Rheumatol. 2020; 2(7): e393-e400. doi: 10.1016/S2665-9913(20)30164-8
20. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2020; 2(6): e325-e331. doi: 10.1016/S2665-9913(20)30127-2
21. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, MartinSilva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: Case series. Ann Rheum Dis. 2020; 79(10): 1381-1382. doi: 10.1136/annrheumdis-2020-217706
22. Fact sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Bamlanivimab. 2020
23. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med. 2021; 384(3): 229-237. doi: 10.1056/NEJMoa2029849
24. Pang J, Xu F, Aondio G, Li Y, Fumagalli A, Lu M, et al. Efficacy and tolerability of Bevacizumab in patients with severe COVID-19. Nat Commun. 2021; 12(1): 814. doi: 10.1038/s41467-021-21085-8.
25. Bevacizumab in severe or critically severe patients with COVID-19 pneumonia – RCT (BEST-RCT). ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/NCT04305106 [Date of access: 07.03.2021].
26. Bevacizumab in severe or critical patients with COVID-19 pneumonia (BEST-CP). ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/NCT04275414 [Date of access: 07.03.2021].
27. Gremese E, Cingolani A, Bosello SL, Alivernini S, Tolusso B, Perniola S, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020; 27: 100553. doi: 10.1016/j.eclinm.2020.100553
28. Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al.; Sarilumab COVID-19 Global Study Group. Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021: S2213-2600(21)00099-0. doi: 10.1016/S2213-2600(21)00099-0
29. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020; 92(7): 814-818. doi: 10.1002/jmv.25801
30. Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: A cautionary case report. Chest. 2020; 158(1): e15-e19. doi: 10.1016/j.chest.2020.04.024
31. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117(20): 10970-10975. doi: 10.1073/pnas.2005615117
32. Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, et al. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020; 99: 491-495. doi: 10.1016/j.ijid.2020.08.024
33. Antonov VN, Ignatova GL, Pribytkova OV, Sleptsova SS, Strebkova EA, Khudyakova EA, et al. Experience of olokizumab use in COVID-19 patients. Therapeutic Archive. 2020; 92(12): 148-154. (In Russ.). doi: 10.26442/00403660.2020.12.200522
34. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020; 384(9): 795-807. doi: 10.1056/NEJMoa2031994
35. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020; 81(2): 318-356. doi: 10.1016/j.jinf.2020.04.017
36. Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020; 81(4): 647-679. doi: 10.1016/j.jinf.2020.06.052
37. Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021. doi: 10.1056/NEJMoa2101643
38. Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkern R, Dulli A, et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes. 2021; 5(3): 605-613. doi: 10.1016/j.mayocpiqo.2021.03.007
39. Avdeev SN, Trushenko NV, Tsareva NA, Yaroshetskiy AI, Merzhoeva ZM, Nuralieva GS, et al. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study. Cytokine. 2021; 146: 155627. doi: 10.1016/j.cyto.2021.155627
40. Pavlov RЕ, Tsarenko SV, Sekinaeva AV, Rybin PN, Nagibinа MV, Soshnikovа EV, et al. Experience with the use of glucocorticoids and netakimab in the treatment of patients with COVID-19 in outpatient settings. Clinical Medicine (Russian Journal). 2020; 98(6): 449-455. (In Russ.). doi: 10.30629/0023-2149-2020-98-6-449-455
41. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021; 384(8): 693-704. doi: 10.1056/NEJMoa2021436
42. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020; 324(13): 1330-1341. doi: 10.1001/jama.2020.17023
43. Li Q, Li W, Jin Y, Xu W, Huang C, Li L, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: A retrospective cohort study. Infect Dis Ther. 2020; 9(4): 823-836. doi: 10.1007/s40121-020-00332-3
44. Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, Ross MJ, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med. 2020; 15(8): 489-493. doi: 10.12788/jhm.3497
45. Chugunov AA, Salikhov VV, Dantseva OV, Kharitonov MA, Rudakov YuV, Bolekhan AV, et al. Some aspects of application glucocorticoid drugs in the complex treatment of new coronaviral infection. Medical Alliance. 2021; 9(1): 43-51. (In Russ.). doi: 10.36422/23076348-2021-9-1-43-51
Review
For citations:
Shirobokov Ya.E., Gladunova E.P., Borodulina E.A., Sukhanova A.E. Overview of potential drugs for the treatment of new coronavirus Infection (COVID-19). Acta Biomedica Scientifica. 2021;6(4):74-86. (In Russ.) https://doi.org/10.29413/ABS.2021-6.4.7
Views:
13913
.png)
Email this article 
